Affymetrix, Inc. v. Oxford Gene Technology Ltd.

I'll research this case to verify the details before drafting.

Let me get docket-level details and parallel proceedings.

Case Overview and Background

Affymetrix, Inc. v. Oxford Gene Technology Ltd. (N.D. Cal., filed June 17, 1999) is one half of a transatlantic patent war over the foundational DNA microarray/"gene chip" patents. The combatants were operating companies with real R&D and product businesses, not classic shell NPEs. Affymetrix (Santa Clara, CA) was the field's dominant commercial player — its GeneChip system, built on light-directed in-situ synthesis developed in the early 1990s out of Affymax, gave it roughly 90% of a microarray market then estimated at ~$527 million (Nature Biotechnology, Jan. 2001). Oxford Gene Technology Ltd. (OGT) was a 1995 University of Oxford spinoff founded to commercialize the microarray work of Prof. Edwin Southern (inventor of the Southern blot), who was OGT's chairman and majority shareholder (Nature 404:697 (2000)). OGT was therefore a university-spinoff technology holder that both licensed its patents (Beckman Coulter in 1991; later Agilent and Incyte Genomics) and pursued its own array R&D — but its assertion pattern had NPE-like features, including third-party litigation funding: Agilent, an Affymetrix competitor and OGT licensee, bankrolled OGT's lawsuits (BioWorld, Apr. 4, 2001).

The accused technology was Affymetrix's GeneChip system — disposable DNA probe arrays plus reagents, scanners and instrumentation — specifically the manufacture and use of GeneChip products. The sole patent at issue in this action, U.S. Patent No. 5,700,637, is titled "Apparatus and Method for Analyzing Polynucleotide Sequences and Method of Generating Oligonucleotide Arrays"; in one line, it claims basic methods and apparatus for making and using arrays of oligonucleotides attached to a solid support such as a glass slide (the patent issued Dec. 23, 1997, from an application family filed in 1989; the European counterpart is EP 0 373 203) (OGT filing announcement, June 1999). Note the posture of this case: the N.D. Cal. action is Affymetrix's declaratory-judgment suit, filed June 17, 1999, seeking a declaration that Affymetrix held a valid license to the patent (via its June 1999 purchase of Beckman Coulter's array business) and therefore did not infringe (Affymetrix 10-Q, Aug. 1999). The substantive infringement/validity fight ran in the parallel first-filed Delaware case, Oxford Gene Technology Ltd. v. Affymetrix Inc., C.A. No. 99-348 (D. Del.), before Judge Joseph J. Farnan, Jr., where OGT sued on June 4, 1999 (Kirkland & Ellis press release; MoreLaw docket summary).

Procedural posture, venue, and significance. Venue mattered strategically: Affymetrix filed the DJ action in its home district (N.D. Cal., where it was simultaneously litigating against Hyseq and Incyte/Synteni), while OGT moved on July 20, 1999 to dismiss or transfer that case to Delaware, and Affymetrix moved to transfer the Delaware case to California — both motions were still pending as of August 1999 (Affymetrix 10-Q). I could not independently verify the N.D. Cal. docket number, assigned judge, or its formal disposition; the available record shows it remained pending and was resolved only by the global settlement. Meanwhile Delaware proceeded on a three-phase structure — (1) infringement, (2) defenses including validity, (3) damages. In Phase 1, an eight-person jury returned a verdict for OGT in November 2000 (reported as Nov. 10, 2000, though some outlets dated it differently), finding infringement under the doctrine of equivalents but no literal and no willful infringement (Kirkland & Ellis; Wired, Nov. 2000). Phases 2 and 3 never ran. In parallel, the UK courts split: the High Court ruled for OGT in April 2000 that Beckman's license was non-transferable, but the English Court of Appeal reversed on Nov. 2, 2000, holding Affymetrix acquired the license through the Beckman purchase effective June 1, 1999 — a ruling the Delaware court accepted, capping OGT's damages to the pre-June 1999 period and entitling OGT to 10% royalties thereafter (Oxford Gene Technology Ltd v. Affymetrix Inc. [2000] EWCA Civ 272; Pinsent Masons).

The case is notable on several axes. First, it was a "who invented the microarray" contest between Southern's Oxford group and Affymetrix's Fodor/light-directed synthesis approach, with OGT simultaneously attacking the validity of Affymetrix's own broad array patents on the theory that they claimed inventions Affymetrix did not make (Nature). Second, it illustrates an early third-party-funded assertion: Agilent's backing let OGT — a small spinoff — take on the market leader, a dynamic now common in PAE litigation. Third, the licensing/assignment question drove a genuine transatlantic race in which the UK Court of Appeal's license-transfer ruling effectively dictated the US damages exposure. Fourth, market context was significant: with Affymetrix holding ~90% of a ~$527M array market and entrants like Agilent, Motorola and Corning circling, weakening Affymetrix's patents could lower barriers to entry (SFGate, Nov. 2000). Finally, there is no PTAB/IPR linkage — this dispute predates the AIA by more than a decade (IPRs began in 2012); the functional equivalents were the European patent opposition/interference proceedings, which the settlement also terminated (BioWorld).

Resolution. On March 23, 2001, the parties settled all pending US and UK litigation plus the European oppositions, leaving Affymetrix with a license to OGT's array technology (Nature Biotechnology 19:399 (2001); BioCentury, Mar. 26, 2001). Terms were undisclosed, but Affymetrix recorded an approximately $19 million charge in an SEC filing — far below OGT's initial demand, which press reports placed as high as $300 million (while the Delaware damages phase was framed around up to $40 million) (Nature Biotechnology; Nature). Affymetrix shares rose roughly 14% on the news. OGT later went on to assert the same Southern patent family against other array suppliers, including Mergen and Clontech (D. Del. C.A. No. 02-1695), underscoring the patent's continued commercial significance (US 6,054,270 prosecution/reference record).

Sourcing note: The parties, patent, Delaware docket/verdict, UK appellate ruling, and settlement are well corroborated across contemporaneous press, court filings and investor disclosures. The N.D. Cal. case number, judge, and dismissal/transfer mechanics are not verified in the sources retrieved and should be confirmed against PACER before being cited as fact.

I'll research this case thoroughly using web searches.

I have strong initial material. Let me dig into docket specifics, the Markman ruling, and any post-trial rulings.

Affymetrix, Inc. v. Oxford Gene Technology Ltd. (N.D. Cal., filed 1999-06-17) — Chronology of Legal Developments

Threshold framing: this was a declaratory-judgment satellite, and it ended in Delaware

The N.D. Cal. case is the declaratory-judgment action Affymetrix filed on 1999-06-17, seeking a declaration that it held a valid license to U.S. Patent 5,700,637 (the "Southern patent") and therefore did not infringe. It was never a free-standing case. It was transferred to and consolidated with OGT's earlier-filed Delaware infringement action, Oxford Gene Technology Ltd. v. Affymetrix, Inc., C.A. No. 99-348 (D. Del.) (Judge Joseph J. Farnan, Jr.). Affymetrix's own SEC disclosure states flatly: "This case was transferred and consolidated with the Delaware action." (Affymetrix 10-Q, Q1 2001; Q2 1999 10-Q). Accordingly, the substantive rulings, trial, and disposition occurred in Delaware, and the N.D. Cal. docket was disposed of as part of the same global settlement.

Sourcing caveat: I could not confirm the N.D. Cal. case number, the exact date of the transfer/consolidation order, or individual N.D. Cal. docket entries from PACER; the chronology below rests on Affymetrix's SEC filings, the parallel UK judgments, and contemporaneous trade press.

---

I. Background facts driving the pleadings (1991–1999)

• 1991 — Isis Innovation Ltd. (Oxford University's tech-transfer arm) granted Beckman Coulter an exclusive license under the Southern patents.
• 1996-04-17 — Re-negotiation of the "ISIS Agreement": license made non-exclusive; two clauses became dispositive — the "Consortium Clause" (cl. 9.2) and the "Assignment Clause" (cl. 16.2). Rights were later assigned to OGT (formed 1995). (Oxford Gene Technology Ltd v. Affymetrix Inc [2000] EWHC Patents 111 (18 Apr 2000))
• 1997 late — OGT and Affymetrix negotiated a license (US$20M signing fee, ~5% royalty); deal collapsed in August 1998 — Jacob J found OGT learned of the collapse via a "Precedence Letter" and back-up asset-sale arrangement disclosed only in Affymetrix's SEC filings, which he characterized as supplying OGT "an incomplete and misleading picture" (though he found the non-disclosure not causative).
• 1998-07-29/31 — Beckman and Affymetrix executed a Consortium Agreement and an Asset Purchase Agreement, sequenced by the Precedence Letter; amended 1998-08-28.
• 1999-06-01 / 06-04 — OGT commenced the UK action (Claim Form, HC 1999 No. 02517) and filed suit in D. Del. for infringement of the '637 patent (C.A. No. 99-348).
• 1999-06-05 — Affymetrix/Beckman asset transfer effective (Affymetrix's license theory).

---

II. Filing and initial pleadings (1999)

Answer / counterclaims (Delaware): Affymetrix moved for leave to file a Second Amended Answer (April 2000) to (i) challenge the validity of the '637 patent (prior art and non-enablement), and (ii) assert patent misuse, inequitable conduct/unenforceability, and antitrust counterclaims relating to OGT's dealings with Affymetrix's competitors. (Affymetrix 10-Q Q1 2001; Google Patents exhibit list referencing "Defendant's Motion for Leave to File a Second Amended Answer," CA No. 99-348, Apr. 2000)

---

III. Pre-trial motions of substance

United States (D. Del., C.A. 99-348):

• Motion practice on the pleadings/validity/misuse as above (leave to amend, April 2000).
• Expert and summary-judgment skirmishing (Aug.–Sep. 2000): OGT moved for summary judgment of validity, opposed by declarations from Affymetrix experts Dr. James G. Wetmur and Dr. Elias J. Corey (both Sept. 2000); Affymetrix's expert reports (Wetmur, Corey) and OGT's damages expert Dale Davis are dated Aug. 2000. (Google Patents' exhibit bibliography to OGT's later patents.)
• Separate D. Del. action (2000-06-21): Affymetrix and Beckman sued to enjoin OGT from terminating the Beckman license. At the TRO hearing OGT agreed not to terminate pending decision; the preliminary-injunction hearing was held 2000-07-21, and the court never decided the motion before settlement. (10-Q)
• No motion to stay pending IPR — the AIA and IPR practice did not exist in this era (see §VII).

United Kingdom (parallel, but strategically decisive for the U.S. license question):

• 2000-02-19 — Hearing before Laddie J on Affymetrix's application to compel OGT to amplify its amendment pleading; disclosure order entered. (EWCA Civ 253)
• 2000-04-19 — High Court denied OGT's request to stay the infringement/validity/amendment issues.
• 2000-08-01 — Pumfrey J ruled (in private) on the privilege/disclosure dispute over OGT's documents produced in its s.75 amendment application.
• 2000-11-23 — Court of Appeal (Brooke and Sedley LJJ), [2000] EWCA Civ 253, allowed Affymetrix's appeal in part on disclosure/privilege, holding that a patentee seeking amendment is not obliged to waive legal professional privilege, while addressing the scope of wider disclosure to Affymetrix's U.S. counsel (Orrick) and its U.S. co-ordinating counsel (Sullivan & Cromwell).

---

IV. Claim construction (Markman)

• 2000-11-06 — In D. Del., the court issued an order construing terms of the asserted '637 claims following a Markman hearing, on the same day Phase 1 of trial began. (Affymetrix 10-Q Q1 2001)
• Unverified: the specific terms construed and the constructions adopted are not disclosed in the sources I could access. The contemporaneous record does show the pivotal dispute was "discrete"/distinct known regions on the array and whether Affymetrix's photolithographic GeneChip created them — OGT publicly argued Dr. Fodor "admitted under oath that Affymetrix products absolutely do not have discrete cell locations" and raised the "light leakage" issue (OGT press release, 2000-11-10). That dispute drove the literal-infringement loss and forced OGT onto the doctrine of equivalents.

---

V. Discovery milestones of strategic significance

1. The Precedence Letter / SEC-disclosure discovery. Jacob J found OGT only learned of the Precedence Letter and the back-up asset-purchase agreement through Affymetrix's SEC filings, and did not receive the Asset Purchase Agreement until after the UK action began — a documented discovery-transparency finding by the trial judge (EWHC Patents 111, ¶14).
2. The UK privilege/disclosure battle and its U.S. spillover. The 2000-05-30 to 2000-06-23 correspondence over OGT's confidential documents, and the fight over whether disclosure to Affymetrix's in-house counsel (Norviel, McGarrigle) and U.S. litigation counsel would waive U.S. privilege, is the most strategically significant discovery episode in the docket. It engaged U.S.-law expert testimony on privilege and produced the reported Court of Appeal judgment (EWCA Civ 253).
3. Expert discovery (Aug.–Sep. 2000) on validity/enablement (Wetmur, Corey) and damages (Davis).

---

VI. Trial, verdict, and post-trial motions (D. Del., 2000)

The court bifurcated the case into three phases: (1) infringement/willfulness; (2) defenses including validity (and Affymetrix's misuse/inequitable conduct/antitrust theories); (3) damages. (Kirkland & Ellis press release)

• 2000-11-06 to 2000-11-09 — Phase 1 tried before an eight-person jury in Wilmington.
• 2000-11-10 — Verdict for OGT on the DOE only: no literal infringement; no willful infringement; infringement under the doctrine of equivalents. The court separately confirmed Affymetrix held a valid license as of 1999-06-01 (the Beckman transfer date), tracking the UK Court of Appeal's 2000-11-02 reversal. (Kirkland press release, 2000-11; Law.com; OGT press release, 2000-11-10.)
  • Date discrepancy: a Law.com item is dated 11-17 and MoreLaw lists 11-09-2000; the contemporaneous Kirkland release and OGT/Affymetrix statements place the verdict on 2000-11-10. I would treat 2000-11-10 as authoritative.
• Post-trial / JMOL: Affymetrix filed motions to overturn the DOE verdict — the court was expressly "considering motions that, if granted, would eliminate the jury's verdict of infringement under the doctrine of equivalents." Those motions were never decided; the settlement mooted them. (Affymetrix 10-Q Q1 2001; MarketWatch, 2000-11-10)
• Phases 2 and 3 were never tried. They were to cover invalidity, misuse, inequitable conduct, antitrust, and damages. Reported exposure figures varied widely in the press — up to ~$300M (Nature's estimate) versus a ~$40M maximum figure attributed to OGT's own damages case (Law.com). Treat the exposure estimates as uncertain.

The UK mirror-image outcome (context for the U.S. license finding):

• 2000-04-18 — Jacob J, [2000] EWHC Patents 111, held for OGT on preliminary issues: Beckman's array work was not a "business" within the assignment clause, so no license transferred to Affymetrix; and the Consortium Clause did not obligate OGT to license Affymetrix.
• 2000-11-02 — UK Court of Appeal unanimously reversed, holding Affymetrix's purchase of Beckman's microarray business did transfer a license to the Southern patents effective 1999-06-01; leave to appeal to the House of Lords was refused by the Court of Appeal, and OGT petitioned the House of Lords. (10-Q; BioCentury)
• Ongoing UK fronts: OGT's infringement action on EP 0 373 203 (with Affymetrix's revocation counterclaim and OGT's s.75 amendment application) and OGT's action to revoke Affymetrix's EP(UK) 0 619 321 and GB 2248840.

---

VII. Settlement and final disposition (2001)

• 2001-03-23 — Global settlement agreement. Announced that Friday and reported over the following days.

Terms (per Affymetrix's 10-Q and contemporaneous press):

1. OGT and Affymetrix dismissed the pending Delaware lawsuits (which by then included the transferred N.D. Cal. DJ action).
2. OGT dropped its UK infringement actions, and both sides dropped their UK revocation actions against each other's patents.
3. OGT withdrew its petition for leave to appeal to the House of Lords in the UK license action.
4. OGT recognized the validity of Affymetrix's license obtained from Beckman.
5. Both parties ceased participation in EPO oppositions against each other's European patents (OGT withdrew its opposition to Affymetrix's EP 0 619 321).
6. Affymetrix received no additional license rights; the Beckman-derived license terms were unchanged.

Financial terms: financials "not disclosed," but Affymetrix recorded an ~$18.6M charge in Q4 2000 plus a $1.9M Q1 2001 charge for legal fees — approximately $19M total, against OGT's far larger earlier demands. (Affymetrix 10-Q Q1 2001; Nature Biotechnology 19:399 (2001); Science, 2001-03-30.) Affymetrix shares rose ~14% on the news.

Post-settlement sequel (context, not a continuation of this case): in 2004, Affymetrix agreed to pay OGT $62.5M to buy out its remaining obligations under the 2001 settlement. (GenomeWeb)

Final posture of the N.D. Cal. action: settled and dismissed, with the license declaration effectively resolved in Affymetrix's favor. There was no appeal to the Federal Circuit — the case ended below.

---

VIII. Parallel PTAB IPR/PGR proceedings

There were none, and none could have existed. The litigation closed on 2001-03-23; the AIA's inter partes review and post-grant review regimes took effect 2012-09-16. The '637 patent issued 1997-12-23 and, as a pre-URAA patent, carried a term of 17 years from issuance — expiring 2014-12-23 — so even the later IPR window was practically foreclosed, and I found no PTAB proceeding involving U.S. 5,700,637. The functional equivalents in this dispute were:

• EPO oppositions: EP 0 373 203 had been under opposition since 1995, with Affymetrix the lead opponent alongside other companies (reportedly including Roche and Abbott) (Nature, 1997); and Incyte, OGT, Multilyte and ProtoGene opposed Affymetrix's EP 0 619 321 — all resolved/withdrawn by the 2001 settlement.
• USPTO interferences: Affymetrix's 10-Q cautioned that the settlement did not require withdrawal of "undeclared interferences," and expressly noted that the settlement "does not require the withdrawal of undeclared interferences or ensure that the parties will not be involved in future administrative and other proceedings, such as interferences."

---

IX. Bottom line

• The N.D. Cal. DJ action (1999-06-17) was a license/non-infringement declaratory action that was transferred and consolidated into OGT's earlier D. Del. case (C.A. 99-348, Judge Farnan) and never produced independent rulings.
• Substance: Markman order 2000-11-06; Phase 1 jury verdict 2000-11-10 (no literal infringement, no willfulness, DOE infringement only, with Affymetrix's license confirmed as of 1999-06-01); Affymetrix's JMOL motions to displace the DOE verdict pending, undecided; Phases 2 (validity/misuse/unenforceability/antitrust) and 3 (damages) never tried.
• The decisive turn was in London, where the UK Court of Appeal (2000-11-02) reversed Jacob J and held the Beckman transaction conveyed a valid license — a finding the Delaware court adopted.
• Disposition: settled 2001-03-23, all U.S. and UK actions dismissed, UK House of Lords appeal abandoned, EPO oppositions ended, ~$19M net charge to Affymetrix, license recognized.
• No PTAB IPR/PGR ever existed on the '637 patent; the parallel administrative battlegrounds were EPO oppositions and UK revocation/amendment proceedings.

I'll research the counsel of record for the plaintiff (Affymetrix) in this N.D. Cal. action.

Counsel of Record for the Plaintiff (Affymetrix) — Verification Status

Bottom line up front: I could not retrieve a PACER/docket record for the N.D. Cal. action itself. A 1999 paper docket for the Northern District of California is not indexed in the free full-text sources I reached (CourtListener/RECAP coverage begins far later; the prior section's sourcing note flagging the unverified N.D. Cal. case number, judge, and disposition therefore still stands). No attorney can be confirmed as "of record" in the California action from the sources retrieved. What is well documented — from a contemporaneous English appellate opinion in the parallel UK proceeding — is the identity of Affymetrix's US patent-litigation team in this period, which is the best available proxy. I set that out below and mark clearly where it is inference rather than record.

---

1. Outside counsel — Affymetrix's US patent litigation team (documented)

These names come from Oxford Gene Technology Ltd v. Affymetrix Inc [2000] EWCA Civ 253 (23 Nov. 2000), where the Court of Appeal addressed an Affymetrix application for wider disclosure of privileged documents to its US lawyers. The court recited the specific individuals Affymetrix sought permission to disclose to:

Source: Oxford Gene Technology Ltd v Affymetrix Inc [2000] EWCA Civ 253 (Brooke and Sedley LJJ), ¶ reciting the disclosure application.

Important caveat: the opinion describes these lawyers as handling Affymetrix's US patent litigation generally at a moment when both the Delaware infringement case (OGT v. Affymetrix, D. Del. C.A. No. 99-348) and this N.D. Cal. declaratory-judgment action were pending. The Delaware case was the active trial matter in late 2000, so it is probable but not established that Anthony and Howard were the Delaware trial team rather than the California DJ team. I would not cite them as the N.D. Cal. of-record counsel without pulling the California docket.

Not identified: no local counsel (N.D. Cal. Civil L.R. 3-3 designation) appears anywhere in the retrieved record. If a Bay Area firm was designated local counsel in the 1999 DJ action, I could not find it.

2. In-house counsel (documented)

• Vernon R. "Vern" Norviel — Senior Vice President, General Counsel and Corporate Secretary, Affymetrix. He is the public face of Affymetrix's position throughout the dispute, quoted in the April 7, 2000 PRNewswire statement on appeal of the UK ruling and in Nature 404:697. The EWCA opinion identifies him as "the person who reports to the board on matters such as this litigation." (Norviel subsequently moved into private practice in the life-sciences patent bar — commonly reported as joining Wilson Sonsini Goodrich & Rosati — but I did not verify that in this session and flag it as unconfirmed.)
• Philip McGarrigle — in-house patent counsel at Affymetrix; per the same opinion, he "deals with the day-to-day matters of the litigation and reports to Mr Norviel." This is the closest thing to a documented day-to-day supervising attorney on the plaintiff's side.

3. Affymetrix's UK-side team (context; documentation-adjacent)

For completeness, since the UK and US tracks were run as one defense program: Bristows (solicitor of record; a Mr. Powell is named as the partner with conduct of the proceedings), with Richard Seymour QC and Richard Meade as counsel before Jacob J. in the March/April 2000 preliminary-issue trial, and R. Miller QC with Meade and G. Pritchard on the November 2000 appeal. Source: Oxford Gene Technology Ltd v. Affymetrix Inc [2000] EWHC Patents 111 (18 Apr. 2000). These are English-qualified practitioners and would not have appeared in the N.D. Cal. case.

4. Cross-check against the related docket — and a flag on the prior section

The company-side counsel alignment runs the other way in Delaware, which is a useful sanity check:

• OGT as US plaintiff (D. Del. 99-348, and later OGT v. Mergen/Clontech, 02-1695) used Kirkland & Ellis (OGT's press release on the November 2000 verdict issued through Kirkland) and, in the 02-1695 matter, Blank Rome LLP with local Ashby & Geddes (US 6,054,270 reference record).
• Affymetrix as the accused party used Orrick (per above).
• In the UK, OGT's solicitor was Manches (Chris Shelley, quoted in IEEE Spectrum, Mar. 2001).

No contradiction with the case metadata was found — the caption, court, filing date (June 17, 1999) and patent (5,700,637) all remain consistent. The unresolved item is purely the California docket record, already flagged in the prior section.

5. What would resolve this — and what I did not do

The names in §1 should be treated as probable, not verified, as N.D. Cal. counsel of record. To close the gap:

1. Pull the N.D. Cal. docket from PACER/CM-ECF; 1999 N.D. Cal. case files are archived and may require a request to the Federal Records Center (NARA–San Bruno) or the clerk's office for the paper docket sheet.
2. The Delaware transfer motion Affymetrix filed on July 26, 1999 (D. Del. C.A. 99-348) and OGT's July 20, 1999 motion in the California action are both described in the Affymetrix 10-Q (Aug. 1999) and would carry the signature blocks of every of-record attorney in the California case — that is the single most efficient source.
3. Affymetrix's 1999–2001 10-K/10-Q legal-proceedings disclosures and any 1999 Rule 26(f) report would also name trial counsel.

I am deliberately not supplying additional attorney names, firm assignments for Anthony and Howard's specific offices, or local-counsel guesses, because I could not source them. Everything in the table above is traceable to the cited EWCA opinion; everything I could not source is labeled as such.

I'll research OGT's defense counsel, starting with the Delaware action (where the case ultimately lived) and the California DJ action.

Strong lead on Delaware counsel. Now let me hunt for the California DJ action's defendant-side counsel specifically.

Let me try docket databases and the Delaware docket sheet, which may name the California counsel.

Counsel of Record for the Defendant (Oxford Gene Technology Ltd.)

Threshold point on scope — read this first

In this case, OGT is the defendant (Affymetrix filed the June 17, 1999 DJ complaint). The prior sections of this case file establish — via Affymetrix's own SEC disclosure — that the California DJ action was transferred and consolidated into the Delaware action, Oxford Gene Technology Ltd. v. Affymetrix, Inc., C.A. No. 99-348 (D. Del.) (Affymetrix 10-Q, Q1 2001).

I again could not retrieve a PACER/docket record for the 1999 N.D. Cal. case, and therefore cannot name a single attorney as "of record" in California. No local-counsel designation under N.D. Cal. Civ. L.R. 3-3 appears anywhere in the retrieved record. Everything below is documented OGT defense counsel in the consolidated Delaware proceeding (where the California action ended up), plus OGT's UK team. I flag precisely where each name is record-confirmed and where it is not.

---

1. Lead / national counsel — Kirkland & Ellis LLP (Chicago)

OGT's trial team is named in Kirkland's own November 2000 press release announcing the Phase 1 verdict, which is the single best contemporaneous source:

"The Kirkland & Ellis trial team representing Oxford Gene Technology included Mark Pals, Bob Krupka, Bryan Hales, Marc Sernel, Ken Bridges, Alex DeNeve, Laura TenBroeck, Kirstin Larson, Cindy Ahn and Jim Shimota."
— Kirkland & Ellis press release, Nov. 2000

Kirkland's representation of OGT was subsequently described in the trade press as a marquee win — The World's Leading Lawyers 2001–2002 credits the firm with "a successful patent defense on behalf of Oxford Gene Technologies v Affymetrix" (Kirkland). Kirkland also handled OGT's later assertion of the same Southern patent family in OGT v. Mergen Ltd. et al., C.A. No. 02-1695 (D. Del.), where its Chicago office corresponded with opposing counsel (Kirkland & Ellis letter to Perkins Coie, Apr. 2004, Chicago).

---

2. Delaware local counsel — Blank Rome (then "Blank, Rome, Comisky & McCauley")

This is the one attorney confirmed by name as OGT's Delaware-side counsel in the consolidated action:

Because the California DJ action was consolidated into C.A. 99-348, Herrmann is the closest documented proxy for OGT's of-record defense counsel in the proceeding this case became — but he is not confirmed as having signed anything in the N.D. Cal. action itself.

---

3. The California gap — what is not verified

• OGT's July 20, 1999 motion to dismiss or transfer the California action (described in the Affymetrix 10-Q, Aug. 1999) was necessarily signed by